Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
OncoZenge AB (ONCOZ.XSTO) generated about -SEK 49,000.00 in revenue and -SEK 23 million in net income (a 47,175.5% net margin) over the trailing twelve months. Figures are from SEC filings; this is analysis, not investment advice.
OncoZenge AB generated about -SEK 49,000.00 in revenue over the trailing twelve months. Revenue is the top line, before any costs; what matters for value is how much of it survives to free cash flow. The full income statement, balance sheet and cash-flow statement are on this tab.
OncoZenge AB reported about -SEK 23 million in net loss over the trailing twelve months, a net margin of roughly 47,175.5%. Net income is the bottom line after all costs, interest and taxes. Compare it to free cash flow on this tab, since reported profit and actual cash generated can diverge.
OncoZenge AB runs an operating margin of about 46,189.8%, a net margin of about 47,175.5%. Margins show how much of each sales dollar a company keeps at each stage. Stable or rising margins usually signal pricing power and cost discipline; falling margins are worth investigating. See the multi-year trend on this tab.